Ignite Creation Date:
2025-12-25 @ 2:47 AM
Ignite Modification Date:
2025-12-26 @ 1:28 AM
Study NCT ID:
NCT03553433
Status:
UNKNOWN
Last Update Posted:
2018-06-12
First Post:
2018-04-18
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D011537', 'term': 'Pruritus'}], 'ancestors': [{'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D012877', 'term': 'Skin Manifestations'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C505730', 'term': 'apremilast'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR'], 'maskingDescription': 'Double-blind'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 90}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2018-06', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2018-06', 'completionDateStruct': {'date': '2020-06', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2018-06-11', 'studyFirstSubmitDate': '2018-04-18', 'studyFirstSubmitQcDate': '2018-06-11', 'lastUpdatePostDateStruct': {'date': '2018-06-12', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2018-06-12', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-12', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Scalp VAS Pruritus assessment', 'timeFrame': 'Weeks 16', 'description': 'Pruritus VAS Scale (0 - 100)'}], 'secondaryOutcomes': [{'measure': 'Scalp VAS Pruritus assessment', 'timeFrame': 'Weeks 0, 4, 32, 52', 'description': 'Pruritus VAS Scale (0 - 100)'}, {'measure': '% BSA', 'timeFrame': 'Weeks 0, 4, 16, 32, 52', 'description': 'Body surface area'}, {'measure': '% BSA of scalp', 'timeFrame': 'Weeks 0, 4, 16, 32, 52', 'description': 'Body surface area of scalp'}, {'measure': 'PrecisePASI', 'timeFrame': 'Weeks 0, 4, 16, 32, 52', 'description': 'Psoriasis Area and Severity Index, modified to measure in percentages'}, {'measure': 'PGA', 'timeFrame': 'Weeks 0, 4, 16, 32, 52', 'description': 'Physicians Global Assessment (0 - 5)'}, {'measure': 'Scalp-PGA', 'timeFrame': 'Weeks 0, 4, 16, 32, 52', 'description': 'Physicians Global Assessment of the Scalp (0 - 5)'}, {'measure': 'DLQI', 'timeFrame': 'Weeks 0, 4, 16, 32, 52', 'description': 'Skin related Quality of life (0 to 30)'}, {'measure': 'Scalpdex', 'timeFrame': 'Weeks 0, 4, 16, 32, 52', 'description': '23 items related to scalp symptoms'}, {'measure': 'PSSI', 'timeFrame': 'Weeks 0, 4, 16, 32, 52', 'description': 'Psoriasis score measuring intensity on the scalp'}, {'measure': 'VAS pruritus assessment', 'timeFrame': 'Weeks 0, 4, 16, 32, 52', 'description': 'Pruritus VAS Scale (0 - 100)'}, {'measure': 'EQ-5D', 'timeFrame': 'Weeks 0, 4, 16, 32, 52', 'description': 'Health-related Quality of Life Instrument'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['apremilast', 'quality of life', 'pruritus', 'oral drug', 'placebo'], 'conditions': ['Psoriasis of Scalp', 'Psoriasis Vulgaris']}, 'descriptionModule': {'briefSummary': 'A phase 4 multicenter, randomized, placebo-controlled Study evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients with moderate-to-severe Scalp Psoriasis', 'detailedDescription': 'The scalp is the most frequently affected body region in psoriasis. Scalp Psoriasis can impair the quality of life greatly due to pruritus. This is however not usually investigated as a primary outcome of treatments.\n\nThis study will investigate the effects of apremilast on the pruritus and quality of life and other patient reported outcomes in patients with scalp psoriasis.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion criteria:\n\n1. Adult (\\>18yrs);\n2. Signed informed consent\n3. Clinical diagnosis of chronic plaque psoriasis for at least 3 months as determined by the subject's medical history and confirmation of diagnosis through physical examination by the Investigator;\n4. Psoriatic lesions with DLQI \\>10 and involvement of \\>20% of the scalp and pruritus with a VAS score of \\> 50 (0-100);\n5. Candidate for systemic therapy;\n6. Females who are of child-bearing potential should be practicing birth control throughout the study and for 70 days after the last dose of study drug;\n7. Subject is judged to be in good health as determined by the Investigator based upon the results of medical history, laboratory profile and physical examination.\n8. Creatinine \\< 80 umol/l at Inclusion\n\nExclusion criteria:\n\n1. Erythrodermic Ps, medication-induced or medication-exacerbated Ps or new onset guttate Ps or other skin conditions at the time of the screening visit (e.g. eczema) that would interfere with evaluations of the effect of the investigational product on Ps;\n2. Use of any anti-psoriatic therapy last administered less than 4 weeks of start of study drug such as\n\n 1. Three months or 5 PK half-lives, whichever is longer, for biologics tumor necrosis factor (TNF) antagonists, interleukin (IL) 12/23/17 inhibitors or other biologic drugs\n 2. 4 weeks for immunosuppressive / -modulating drugs including cyclosporine A, methotrexate, azathioprine, mycophenolate mofetil, fumaric acid esters, retinoids, JAK inhibitors, corticosteroids, any other experimental drug, etc.\n 3. Topical medications (eg. Corticosteroids) except coal tar shampoo, and/or salicylic acid scalp preparations on scalp lesions.\n 4. 4 weeks for phototherapy (ie, UVB, PUVA).\n3. Infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days prior to the Baseline visit or oral anti-infectives within 14 days prior to the Baseline visit;\n4. Positive serology for hepatitis B, hepatitis C, HIV indicating acute or chronic infection;\n5. Chronic recurring bacterial infections or active TB;\n6. Positive pregnancy test at Screening or at the Baseline visit;\n7. Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study;\n8. History of clinically significant alcohol or drug abuse in the last 12 months;\n9. Known hypersensitivity to the excipients of Otezla® as stated in the label;\n10. Subject is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.\n11. Prior history of suicide attempt at any time in the subject's life time prior to signing the informed consent and randomization, or major psychiatric illness requiring hospitalization within the last 3 years prior to signing the informed consent."}, 'identificationModule': {'nctId': 'NCT03553433', 'acronym': 'APRESCALP', 'briefTitle': 'Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis', 'organization': {'class': 'OTHER', 'fullName': 'University of Zurich'}, 'officialTitle': 'A Phase 4 Multicenter, Randomized, Placebo-controlled Study Evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients With Moderate-to-severe Scalp Psoriasis', 'orgStudyIdInfo': {'id': 'DER-USZ-AAN-021'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Verum', 'description': 'Apremilast 30mg bd', 'interventionNames': ['Drug: Apremilast 30mg']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo Oral Tablet', 'description': 'Excipiens', 'interventionNames': ['Drug: Placebo Oral Tablet']}], 'interventions': [{'name': 'Apremilast 30mg', 'type': 'DRUG', 'otherNames': ['Otezla'], 'description': 'Anti-psoriatic drug', 'armGroupLabels': ['Verum']}, {'name': 'Placebo Oral Tablet', 'type': 'DRUG', 'otherNames': ['Placebo'], 'description': 'Indistinguishable tablets not containing apremilast, Placebo Oral Tablet', 'armGroupLabels': ['Placebo Oral Tablet']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Sankt Gallen', 'state': 'Canton of St. Gallen', 'country': 'Switzerland', 'contacts': [{'name': 'Antonio Cozzio, MD PhD', 'role': 'CONTACT', 'email': 'antonio.cozzio@kssg.ch', 'phone': '+41 71 494 20 30'}], 'facility': 'KSSG', 'geoPoint': {'lat': 47.42391, 'lon': 9.37477}}, {'city': 'Bern', 'country': 'Switzerland', 'contacts': [{'name': 'Nikhil Yawalkar, MD', 'role': 'CONTACT', 'email': 'nikhil.yawalkar@insel.ch', 'phone': '+41 (31) 632 22 88'}], 'facility': 'Inselspital', 'geoPoint': {'lat': 46.94809, 'lon': 7.44744}}, {'city': 'Lausanne', 'country': 'Switzerland', 'contacts': [{'name': 'Curdin Conrad, MD', 'role': 'CONTACT', 'email': 'curdin.conrad@chuv.ch', 'phone': '+41 21 314 0400'}], 'facility': 'CHUV', 'geoPoint': {'lat': 46.516, 'lon': 6.63282}}, {'zip': '8091', 'city': 'Zurich', 'country': 'Switzerland', 'facility': 'Department of Dermatology, University Hospital Zurich', 'geoPoint': {'lat': 47.36667, 'lon': 8.55}}], 'centralContacts': [{'name': 'Alexander Navarini, MD PhD', 'role': 'CONTACT', 'email': 'alexander.navarini@usz.ch', 'phone': '0041442551111'}, {'name': 'Karolina Papageorgiou, MD', 'role': 'CONTACT', 'email': 'karolina.papageorgiou@usz.ch', 'phone': '0041442551111'}], 'overallOfficials': [{'name': 'Alexander Navarini, MD PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Zurich'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University of Zurich', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}